ClinVar Miner

Submissions for variant NM_007299.4(BRCA1):c.2070A>G (p.Gln690=) (rs80357286)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000587361 SCV000077015 benign not provided 2019-02-14 criteria provided, single submitter clinical testing
Ambry Genetics RCV000131632 SCV000186655 benign Hereditary cancer-predisposing syndrome 2014-07-08 criteria provided, single submitter clinical testing
GeneDx RCV000441215 SCV000527062 likely benign not specified 2017-02-02 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000441215 SCV000602704 likely benign not specified 2016-11-04 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000587361 SCV000699256 likely benign not provided 2016-03-24 criteria provided, single submitter clinical testing Variant summary: The BRCA1 c.5456A>G variant affects a non-conserved nucleotide, resulting in amino acid change from a medium size and polar Asparagine (N) to a small size and polar Serine (S). 4/4 in-silico tools predict benign outcome for this variant (SNPs&GO not captured due to low reliability index). Functional assays support these in silico predictions of a benign outcome. Homology directed recombination is not impaired by this missense mutation (Lu_BRCA_Nature Comms_2015), nor is the activity of this BRCT domain variant in transcriptional activation (Lee_CR_2010 ) . Pavlicek et al._2004 predicted the variant to lead to a conservative substitution also implicating a neutral outcome. This variant was found in 4/121402 control chromosomes at a frequency of 0.0000329, which does not significantly exceed maximal expected frequency of a pathogenic BRCA1 allele (0.0010005). There is at least one HBOC family reported to have the variant in the literature but this report lacks clinical, co-segregation, and control data, therefore it does not permit establishment of a cause-effect relationship between the variant and HBOC (Judkins_Cancer Res_2005). In addition, several reputable clinical laboratories classified this variant as benign without evidence to independently evaluate. There have been no reports of pathogenic co-occurrences in patients. Functional evidence strongly support a benign outcome, thus this missense BRCA1 variant is classified as likely benign until co-occurrence or co-segregation data are available.
Color RCV000131632 SCV000911447 benign Hereditary cancer-predisposing syndrome 2016-10-31 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000587361 SCV001133635 benign not provided 2019-05-30 criteria provided, single submitter clinical testing
Sharing Clinical Reports Project (SCRP) RCV000077625 SCV000109428 benign Breast-ovarian cancer, familial 1 2012-05-01 no assertion criteria provided clinical testing
Breast Cancer Information Core (BIC) (BRCA1) RCV000077625 SCV000145519 uncertain significance Breast-ovarian cancer, familial 1 1997-02-15 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.